Address: Suite 2A-C, Liguanea Post Office Mall, 115 Hope Road, Kingston 6, Jamaica | Tel: (876) 978-4009-10, (876) 631- 4000, Fax : (876) 631-4070

PUBLISHED: Fluoroscopy-guided intra-articular sacroiliac joint steroid injection for sacroiliitis in ankylosing spondylitis: a Case Report


A fundamental clinical feature of ankylosing spondylitis (AS) is sacroiliitis, which is inflammation of the sacroiliac joints. It is characterized by back pain and stiffness affecting the sacroiliac joint and axial skeleton (1–3). The sacroiliac joint is commonly the first joint involved and may also be the most painful symptomatically. While the aetiology of AS is unknown, genetic and environmental factors play a major role. The prevalence of AS is approximately 0.1–1% in the general population (4, 5) and onset of this potentially debilitating disease may occur as early as in childhood. However, onset is usually in the second and third decades of life and affects men two to three times more often than women (6, 7). Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroid and disease-modifying antirheumatic drugs (DMARDs) have been used to treat patients withAS (2) and fluoroscopy-guided intra-articular sacroiliac joint (IASIJ) steroid injection has been incorporated in the treatment of sacroiliitis (8, 9).



A 20-year old male gave a history of having undifferentiated inflammatory type cervical, thoracic and lumbar spine pain as well as right sacroiliac joint pain, rib/costochondrial pain and variable peripheral arthritis affecting the right hip, ankles, right rotator cuff and bilateral epicondylitis since 2010. He was subsequently diagnosed with AS in 2012. He then presented to the University Hospital of the West Indies (UHWI), Physical Medicine and Rehabilitation (PMR) clinic with a two-month flare-up of pain in the right groin, right buttock and low back. His presenting visual analogue scale (VAS) pain score on the 11-point Likert scale was 4/10 in the right groin which intensifies with walking (8/10), and right low back pain (5/10) which worsens to 7/10 on waking in the morning. He was evaluated as having an Oswestry Disability Index of 40%moderate disability. Functional impairment assessment using Bath Ankylosing Spondylitis Functional Index (BASFI) was 4.9 out of 10 and active disease evaluation using the Bath Ankylosing Spondylitis Disease Activity Index was 7.3 out 10.

He was being treated by a rheumatologist and current medication included sulfasalazine and non-steroidal anti-inflammatory medication. He had also been treated with Actemra (tocilizumab) which controlled the fatigue and generalized inflammatory symptoms. However, his pain persisted. He was placed on amitriptyline and paroxetine for depression. Physical therapy was also incorporated in his treatment and he was also lifting light weights at the gym a few days per week. On examination, he was found to walk with a normal gait. He was able to heel and toe walk, but heel walking worsened the right low back pain. Bilateral lower extremities reflexes were 3+ and symmetrical. His strength was normal grade 5/5 in both lower extremities and sensation was intact. Straight leg raise was negative. Slump sit test was positive on right but negative on the left side. Pelvic anterioposterior glide and pelvic compression tests were negative while Patrick’s FABERE (Flexion, Abduction, External Rotation and Extension) and pelvic distraction tests as well as Gaenslen’s sign were positive on the right. There was tenderness on palpation over the right sacroiliac joint.

Radiological findings included: magnetic resonance imaging (MRI) which showed a normal lumbosacral spine and pelvis/hips X-ray which showed bilateral sacroiliitis with evidence of subchondral sclerosis and marginal erosive changes right greater than left (Figure). He was assessed as having sacroiliitis on the right greater than on the left, with the right being symptomatic


Fluoroscopy-guided right sacroiliac joint steroid injection was done. The technique used had the patient position prone. The region overlying the inferior aspect of the right sacroiliac joint was identified using superficial landmarks and fluoroscopy. Under sterile condition, the area over the right sacroiliac joint was cleaned with betadine and draped. A 22-gauge needle was used to anaesthetize the skin using 4 ml of 1%lidocaine. Using fluoroscopic guidance, a 22-gauge quinke needle was used to enter the right sacroiliac joint from below. One millimetre of Omnipaque (iohexol) was used to confirm an intra-articular flow pattern and there was no vascular uptake. He was then injected with 1 ml of triamcinolone 40 mg/ml and 0.8 ml of 1% lidocaine. Pre-procedure VAS at rest was 4/10 and with activity, 6/10. Post-procedure VAS at rest was 0/10 while with activity, 2/10.

At follow-up within a week, the patient reported 95% improvement in the right buttock pain over the sacroiliac joint (SIJ). He rated the right buttock pain VAS of 1/10. He still had low back pain and also complained of right shoulder pain. His Oswestry Disability Index after IASIJ steroid injection was 16% which is rated minimal disability as compared to 40% before injection which is moderate disability. He was also prescribed a sacroiliac joint belt to be worn daily and a pelvic stabilizing rehabilitation programme was outlined.



Ankylosing spondylitis is a progressive inflammatory seronegative autoimmune disease which causes inflammation of the spine and sacroiliac joints, resulting in axial skeleton rigidity and if left untreated can advance to fusion of the spine ie Bamboo spine (10, 11). Sacroiliitis is regarded as a hallmark in diagnosing AS (3). Other clinical presentations include positive HLA-B27 test, radiological findings (including sclerosis or erosion of the sacroiliac joint), low back pain, peripheral arthritis and extra-articular involvement – such as uveitis, and cos tosternal involvement restricting chest expansion – may also occur (2, 6).

The prevalence of AS is highest in the northern European countries, whereas persons of Afro-Caribbean descent have the least (12). The use of NSAIDs and fluoroscopyguided steroid injection is widely used to treat sacroiliitis, along with physical therapy (8, 9). It is to be noted that in the index case, the symptoms of low back pain persisted post IASIJ injection; this is not surprising as the treatment is localized to the site injected. Further treatment must be incorporated for the alleviation of the lumbosacral spine pain. In this case, NSAIDs and DMARDs gave minimal relief of the patient’s sacroiliac joint pain, and intervention with fluoroscopyguided steroid injection for intra-articular capsule injection gave 95% improvement in the patient’s perceived pain, a decrease of VAS from 6/10 with activity to 1/10. Additionally, Oswestry Disability Index improved from 40% moderate disability to 16% minimal disability. This is consistent with a study done by Karabacakoglu et al, who found that fluoroscopy-guided intra-articular corticosteroid instillation in the SIJ may be regarded as an effective therapy since there was a 90.9% (20 of 22 joints) reported improvement (13).



1. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 1971; 3: 213–23.

2. Sieper J, Braun J, RudwalietM, BoonenA, ZinkA. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61 (Suppl 3): iii8–iii18.

3. Creemers MCW. Ankylosing spondylitis: what do we really know about the onset and progression of this disease? J Rheumatol 2002; 29: 1121–3.

4. Maugars Y, Mathis C, Berthelot JM, Charlier C, Prost A. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies. Br J Rheum 1996; 35: 767–70.

5. Hamersma J, Cardon LR, Bradbury L, Brophy S, van der Horst-Bruinsma I, Calin A et al. Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum 2001; 44: 1396–1400.

6. Brophy S, Calin A. Ankylosing spondylitis: interactions between genes, joints, age of onset and disease expression. J Rheumatol 2001; 28: 2283–8.

7. O’Shea FD, Boyle E, Riarh R, Tse SM, Laxer RM, Inman RD. Comparison of clinical and radiographic severity of juvenile-onset vs. adult-onset ankylosing spondylitis. Ann Rheum Dis 2009; 68: 1407–12.

8. Khan MA, Garcia-Kutzbach A, Espinoza LR. Treatment of ankylosing spondylitis: a critical appraisal of non-steroidal anti-inflammatory drugs and corticosteroids. Am J Med Sci 2012; 343: 350–2.

9. Dussault RG, Kaplan PA,AndersonMW. Fluoroscopy-guided sacroiliac joint injection. Radiology 2000; 214: 273–7.

10. Jimenez-Balderas FJ,Mintz G. Ankylosing spondylitis: clinical course in women. J Rheumatol 1993; 20: 2069–72.

11. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheum 1997; 36: 766–71.

12. Kaipiainen-Seppanen O,Aho K, HeliovaaraM. Incidence and prevalence of ankylosing spondylitis in Finland. J Rheumatol 1997; 24: 496–9.

13. Karabacakoglu A, Karakose S, Ozerbil OM, Odev K. Fluoroscopyguided intra-articular corticosteroid injection into the sacroiliac joint in patients with ankylosing spondylitis. Acta Radiol 2002; 43: 525–7.

Dr PUA Dawson,
PhysicalMedicine and Rehabilitation, c/o Dean’s Office,
Faculty of Medical Sciences,
The University of theWest Indies,
Kingston 7, Jamaica,West Indies.


Read the original article